Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-23)		ATTORNEY'S DOCKET NUMBER PB60787
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)
INTERNATIONAL APPLICATION NO. PCT/GB2005/000976	INTERNATIONAL FILING DATE 15-Mar-2005	PRIORITY DATE CLAIMED 16-Mar-2004
TITLE OF INVENTION PYRAZOLO[3.4-b]PYRIDI	NE COMPOUNDS, AND TH	EIR USE AS PDE4 INHIBITORS
APPLICANI(S) FOR DO/EO/US Diane Mary Coe, Caroline M Edlin, Julie Nicole Hamblin, Lindvall, Charlotte Jane Mitc	ary Cook, Anthony William J Martin Redpath Johnson, Pau hell, Alison Judith Redgrave,	ames Cooper, Christopher David I Spencer Jones, Mika Kristian
 [] This is a SECOND or SUI [x] This express request to beg 	in national examination procedures expiration of the applicable time li	r 35 U.S.C. 371. oncerning a filing under 35 U.S.C. 371. (35 U.S.C. 371(f)) at any time rather than mit set in 35 U.S.C. 371(b) and PCT
a. [] is transmitted here b. [x] has been transmitted	Application as filed (35 U.S.C. 37 with (required only if not transmitted by the International Bureau. the application was filed in the Unit	
 [] A translation of the International Application into English (35 U.S.C. 371(c)(2)). 		
a. [] are transmitted her b. [] have been transmit	ewith (required only if not transmitt ted by the International Bureau. e; however, the time limit for makin	der PCT Article 19 (35 U.S.C. 371(c)(3)) ed by the International Bureau). g such amendments has NOT expired.
a. [x] was submitted as 10. [] A translation of the annexe	ne inventor(s) (35 U.S.C. 371(c)(4)) part of the international application	ı.
(35 U.S.C. 371(c)(5)). Items 11. to 16. below concern oth	ter document(s) or information in	cluded:
11. [x] An Information Disclosure 12. [] A copy of the assignment of 13. [x] A FIRST preliminary ame	locument; ndment.	
(Add claim to priority vi 14. [] A SECOND or SUBSEQU 15. [] A substitute specification. 16. [x] Power of Attorney and Co- Statement Under 37 CRF 3	respondence Address Indication Fo	
17. [x] An Abstract on a separate sheet of paper. 18. [x] Copy of Form PCT/ISA/210.		
19. [] Other items or information		